Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPID | Q08752 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24257485 | 0.88 | EGLN1 (0.59) | EGLN1 | |
| SCHEMBL24257764 | 0.82 | EGLN1 (0.53) | EGLN1 | |
| SCHEMBL24257597 | 0.81 | ALDH1A1 (0.47) | PPIDEGLN1ALDH1A1HPGDLMNA | |
| SCHEMBL24257727 | 0.80 | ALDH1A1 (0.47) | PPIDEGLN1L3MBTL1ALDH1A1HPGD | |
| SCHEMBL24257569 | 0.79 | EGLN1 (0.48) | PPIDEGLN1ALDH1A1HPGD | |
| SCHEMBL26260136 | 0.79 | SMN1; SMN2 (0.45) | PPIDEGLN1ALDH1A1HPGDLMNA | |
| SCHEMBL24257486 | 0.78 | EGLN1 (0.59) | EGLN1 | |
| SCHEMBL24257632 | 0.77 | EGLN1 (0.56) | PPIDEGLN1ALDH1A1HPGDLMNA | |
| SCHEMBL26265498 | 0.77 | KMT2A (0.49) | PPIDEGLN1KMT2AMEN1L3MBTL1 | |
| SCHEMBL24257725 | 0.77 | ALDH1A1 (0.43) | PPIDEGLN1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2022036188-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | PPID 1401/4885EGLN1 19/4885KMT2A 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.